Author

Dingjingyu Zhou

Dana-Farber Cancer Institute

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Assay:proteomics· 1

Frequent Co-Authors

Lawrence ShueiD· 2 shared Xin X. ZhouiD· 2 shared Akimasa AdachiiD· 1 shared Andrew C. KruseiD· 1 shared Aoxing ChengiD· 1 shared Apoorva BaluapuriiD· 1 shared Edward P. HarveyiD· 1 shared Eric S. FischeriD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioengineering

Lawrence ShueORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Z-TAC enables custom and combinatorial degradation of cell surface proteins

Dingjingyu Zhou, Lawrence Shue, Sean H Gao, Eric S. Fischer, Ryan A. Flynn, Xin X. Zhou

Z-TAC converts IgG antibodies into cell-surface protein degraders, enabling efficient and sustained degradation of multiple receptors and receptor combinations.

bioRxiv · May 10, 2026 · PreprintBioengineering

GPCR Antagonism via Antibody-Mediated Rewiring of Receptor Trafficking and Degradation

Kaitlin Rhee, Lawrence Shue, Akimasa Adachi, James Osei‐Owusu, Dingjingyu Zhou, Aoxing Cheng, Apoorva Baluapuri, Edward P. Harvey, Karen Adelman, Meredith A. Skiba, Jun Ryul Huh, Andrew C. Kruse, Xin X. Zhou

This paper introduces GTACs, bispecific antibodies that selectively downregulate GPCRs via endocytosis and lysosomal degradation, showing high potency and selectivity for therapeutic targets.

bioRxiv · Aug 8, 2025 · PreprintBioengineering